Esperion - חוב כולל להון ESPR

Esperion Therapeutics (ESPR) is regaining investor confidence following the conclusion of legal disputes. The total liabilities-to-equity ratio on the GURU.Markets time chart reflects the current trend, where 0.00 indicates the level of this metric. Cardiologists value the brand for developing cutting-edge non-statin therapies. Business revenues are based on the sale of patented drugs for patients with cardiac pathologies.

This metric is calculated as the ratio of total liabilities to net equity, reflecting the business's degree of dependence on external financing. It measures the risk of insolvency should the cost of debt servicing rise. For Esperion Therapeutics (ESPR), the debt balance is critical, as the uniqueness of Nexletol must generate the cash flow necessary to repay loans. Analysis of this debt-to-equity financing structure chart allows for an assessment of the company's resilience against statin analogues.